Manufacturing Work Addressing FDA Cmc Information Requests Substantially Completed NDA Resubmission Expected Between December 2026 and January 2027 Kansas City, Kan., Nov. 13, 2026 Globe Newswire -- Cingulate Inc. NASDAQ
Why Is Cingulate Inc. (CING) Stock Up Today?
Updated Nov 17, 2026 7:30 PM ET · Prev Close $3.75
Primary Move Catalyst & Conviction
68% Signal ConvictionUnusual Call buying detected
Options traders are heavily buying calls on CING, with 94% of volume in calls. This suggests bullish institutional positioning.
This stock is significantly outperforming its Pharmaceuticals & Therapeutics sector peers, suggesting a stock-specific catalyst.
Market & Sector Relative Strength
CING outperforming the S&P 500 by +26.51%Options Flow & Execution Desk
Bullish Flow · P/C 0.13Unlock 3 Strike-Verified Options Setups for CING
Our options desk modeled ATM Call Rebound / Continuation, ATM Put Downside Positioning, Long ATM Straddle structures for the Dec 18 expiration cycle, plus live unusual contract strike sweeps and full factor sub-scores.
Recent CING Catalyst Headlines
Verified WireKansas City, Kan., Nov. 10, 2026 Globe Newswire -- Cingulate Inc. Nasdaq Cing , a biopharmaceutical company utilizing its proprietary Precision Timed Release PTR drug delivery platform to develop next-generation pharmace
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS City, Kan., Sept. 17, 2026 Globe Newswire -- Cingulate Inc. Nasdaq Cing , a biopharmaceu
By John Vandermosten, Cfa Nasdaq Cing Read the Full Cing Research Report Cingulate, Inc. Nasdaq Cing reported second quarter 2026 results on August 13 th , 2026. During the three-month period, the company generated no re
1–3 Day Expected Range & Key Level
55% Follow-ThroughWatch for continuation above $4.71
Technical Regime (CING)
MIXED MA TREND1-Year Historical Move Analogs
59 EventsSessions in the past year where CING moved >3.0% up:
Retail & Crowd Sentiment
Very BullishStockTwits messages indicate strong bullish sentiment towards $CING, with traders expecting a sustained rise above $4. There is also anticipation for potential parabolic moves in a related low float China stock, EZGO.
About Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions cha...
Get Instant CING Catalyst Alerts
Receive an email alert when CING triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCING Session & Catalyst FAQ
Why is CING stock up today?
Options traders are heavily buying calls on CING, with 94% of volume in calls. This suggests bullish institutional positioning.
Is CING stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 6.90x relative volume (high participation). Our multi-factor model currently rates CING as HOLD. Review full valuation, quality, and timing signals on the CING Buy or Sell Decision Brief →
What is CING's intrinsic value and expected trading range?
At $4.71, CING's modeled 1-to-3 session range is $4.62 – $4.85, with a key inflection level at $4.95 (resistance). Compare current price against multi-year cash flow projections in the CING Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for CING?
RSI at 51.8 reflects constructive bullish momentum. CING trades at $4.71 relative to its 20-day SMA ($4.71) and 50-day SMA ($4.82), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.